Roden — February 10, 2023 — PureIMS, a clinical stage pharmaceutical company focused on developing and commercializing innovative inhaled therapies for systemic and respiratory diseases, has appointed Frank Lambert to the role of Executive Director Commercialization.
DPI developer PureIMS has announced the appointment of Frank Lambert as Executive Director Commercialization. The appointment is part of the company’s strategy to commercialize its Cyclops™ DPI for partnering and co-development with pharma/biotech companies, thus supporting the development of Cyclops™-based inhalation products for their vaccine/drug of choice. Frank is a seasoned business development professional with a long track record at ICON and PRA HealthSciences.
PureIMS owns exclusive world-wide license rights of Cyclops™, a dry-powder inhaler for rapid and controlled drug delivery, easy-to-use, comfortable, pre-filled, and disposable, ensuring high dose delivery and a fast onset-of-action. Recently the company closed agreements for the application of Cyclops™ in the development of therapeutics for NTM and IPF and for COVID-19-vaccination.
In addition to partnering programs, PureIMS has a clinical stage in-house pipeline also open to partnering; lead programs are Cyclops™ inhalers for levodopa, epinephrine and colistin.
PureIMS said that with Frank’s appointment the company pursues opportunities to further enthuse pharma/biotech companies for early-clinical endeavors looking for innovative pulmonary delivery options to develop small and large molecules for local and systemic indications. The Cyclops™ technology is also ideally suited for ‘rescue applications’ in areas with an acute unmet need.
Jaap Wieling, PureIMS’ CEO commented, “I am very pleased to welcome Frank to our team to capitalize on the opportunities we see for Cyclops™ for a broad range of compounds and indications. Having worked in early-stage clinical pharmacology for so long Frank will bridge Cyclops™ to developers of new delivery products with marketed compounds as well as NCE’s and NBE’s.”
Sent for publication to:
- OINDP News
- FirstWord Pharma
- Fierce Biotech
- Endpoint News
- PureIMS LinkedIn page
- BiotechNews & Life Sciences